Purchase this article with an account.
Andrew Vanslette, Michael McGrath, Monica O'Connor, Charles D Blizzard, Ankita Desai, Michael Bassett, Peter K Jarrett, Arthur Driscoll, Amar Sawhney; Dose Based Pharmacokinetics of Sustained Release Dexamethasone in Beagles. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):238.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of different incremental doses on the pharmacokinetic release profile of dexamethasone when delivered from a sustained release punctum plug (OTX-DP) in a preclinical animal model.
OTX-DP is a punctum plug containing dexamethasone within a biodegradable PEG hydrogel matrix. The hydrogel is conjugated with fluorescein to aid plug visualization. OTX-DP at three different doses (215, 581 and 718 µg per plug) were inserted into the inferior canaliculus of beagles (n=12 per group). Plug retention was assessed through the tissue using blue light with a yellow filter. Tear fluid samples were taken using a Schirmer test strip at predetermined time points and dexamethasone levels were analyzed in the strips by HPLC / MS.
OTX-DP is designed to release dexamethasone into the tear fluid in a tapered profile, as shown in Figure One in the preclinical beagle model. The release of dexamethasone from the punctum plug is regulated by the limited solubility of the dexamethasone in the tear fluid at the interface of the proximal portion of the punctum plug within the canaliculus and by the concentration gradient which is initiated at that interface. A tapered drug release profile is created as the front of the concentration gradient recedes from the proximal portion of the punctum plug due to reduced drug levels. The duration of the drug release can therefore be controlled by regulating dose within the punctum plug, as shown in Figure Two.
Topical corticosteroids treat inflammation for several ophthalmic conditions. The dosing regimen may require multiple daily administrations followed by tapering to a lesser frequency as the inflammation subsides. A one-time administration of OTX-DP at different dosing levels, as demonstrated in the beagle model, can regulate the duration of therapy ensuring that dexamethasone treatment is delivered in a tapered drug release profile.
This PDF is available to Subscribers Only